Previous 10 | Next 10 |
Mesoblast (NASDAQ:MESO) has received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain due to degenerative disc disease refractory to available therapies, including opioids. Following revie...
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedback from the US Food & Drug Administration’s (FDA) Office of Tissues and Advan...
Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re at the halfway point of the week but there’s no slowing down as we dive into the biggest pre-market stock movers for Wednesday! Source: Shutterstock We’ve got earni...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +106%. Nuverra Environmental Solutions (NYSE:NES) +33%. CPS Technologies (NASDAQ:CPSH) +24%. Terminix (NYSE:TMX) +21%. Alzamend Neuro (NASDAQ:ALZN) +17%. MIND Technology (NASDAQ:MIND) +17%. Landec Corporation (NASDAQ:LNDC) +13%. Soliton (NASDAQ:SOLY)...
Adagio Therapeutics (NASDAQ:ADGI) -67% after Omicron led to 300-fold reduction in neutralizing effect in COVID-19 therapy. Aptose Biosciences (NASDAQ:APTO) -32% following ASH data on acute myeloid leukemia candidate. SeaChange International (NASDAQ:SEAC) -22%. Mesoblast (N...
Mesoblast (NASDAQ:MESO) drops 8% premarket after being notified by Novartis (NYSE:NVS) that it has chosen to terminate the agreement with Mesoblast prior to closing. The company develops remestemcel-L in partnership with Novartis. Mesoblast said it remains highly focused on executin...
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing. Mesoblast remains hig...
Mesoblast (NASDAQ:MESO) perks up 5.6% premarket after announcing new analyses from the Phase 3 DREAM-HF trial showing that the greatest treatment benefit from rexlemestrocel-L is in heart failure and low ejection fraction (HFrEF) patients with diabetes and/or ischemia...
Key points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest treatment benefit in major adverse cardiovascular events (MACE) of cardiovascular mor...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...